-DOCSTART- -X- O
The -X- _ O
high -X- _ O
prevalence -X- _ O
of -X- _ O
type -X- _ B-Patient
2 -X- _ I-Patient
diabetes -X- _ I-Patient
mellitus -X- _ I-Patient
in -X- _ O
the -X- _ O
world -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
the -X- _ O
increasing -X- _ O
reports -X- _ O
about -X- _ O
the -X- _ O
adverse -X- _ O
side -X- _ O
effects -X- _ O
of -X- _ O
the -X- _ O
existing -X- _ O
diabetes -X- _ O
treatment -X- _ O
drugs -X- _ O
have -X- _ O
made -X- _ O
developing -X- _ O
new -X- _ O
and -X- _ O
effective -X- _ O
drugs -X- _ O
against -X- _ O
the -X- _ O
disease -X- _ O
a -X- _ O
very -X- _ O
high -X- _ O
priority. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
ten -X- _ B-Outcome
novel -X- _ I-Outcome
compounds -X- _ I-Outcome
found -X- _ I-Outcome
by -X- _ I-Outcome
targeting -X- _ I-Outcome
peroxisome -X- _ I-Outcome
proliferator-activated -X- _ I-Outcome
receptors -X- _ I-Outcome
( -X- _ I-Outcome
PPARs -X- _ I-Outcome
) -X- _ I-Outcome
using -X- _ I-Outcome
virtual -X- _ I-Outcome
screening -X- _ I-Outcome
and -X- _ I-Outcome
core -X- _ I-Outcome
hopping -X- _ I-Outcome
approaches. -X- _ I-Outcome
PPARs -X- _ B-Intervention
have -X- _ O
drawn -X- _ O
increasing -X- _ O
attention -X- _ O
for -X- _ O
developing -X- _ O
novel -X- _ O
drugs -X- _ O
to -X- _ O
treat -X- _ O
diabetes -X- _ B-Patient
due -X- _ O
to -X- _ O
their -X- _ O
unique -X- _ O
functions -X- _ O
in -X- _ O
regulating -X- _ O
glucose -X- _ O
, -X- _ O
lipid -X- _ O
, -X- _ O
and -X- _ O
cholesterol -X- _ O
metabolism. -X- _ O
The -X- _ O
reported -X- _ O
compounds -X- _ O
are -X- _ O
featured -X- _ O
with -X- _ O
dual -X- _ O
functions -X- _ O
, -X- _ O
and -X- _ O
hence -X- _ O
belong -X- _ O
to -X- _ O
the -X- _ O
category -X- _ O
of -X- _ O
dual -X- _ O
agonists. -X- _ O
Compared -X- _ O
with -X- _ O
the -X- _ O
single -X- _ B-Comparison
PPAR -X- _ I-Comparison
agonists -X- _ I-Comparison
, -X- _ O
the -X- _ O
dual -X- _ B-Outcome
PPAR -X- _ I-Outcome
agonists -X- _ I-Outcome
, -X- _ I-Outcome
formed -X- _ I-Outcome
by -X- _ I-Outcome
combining -X- _ I-Outcome
the -X- _ I-Outcome
lipid -X- _ I-Outcome
benefit -X- _ I-Outcome
of -X- _ I-Outcome
PPARα -X- _ I-Outcome
agonists -X- _ I-Outcome
( -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
fibrates -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
glycemic -X- _ I-Outcome
advantages -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
PPARγ -X- _ I-Outcome
agonists -X- _ I-Outcome
( -X- _ I-Outcome
such -X- _ I-Outcome
as -X- _ I-Outcome
thiazolidinediones -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
are -X- _ I-Outcome
much -X- _ I-Outcome
more -X- _ I-Outcome
powerful -X- _ I-Outcome
in -X- _ I-Outcome
treating -X- _ I-Outcome
diabetes -X- _ I-Outcome
because -X- _ I-Outcome
they -X- _ I-Outcome
can -X- _ I-Outcome
enhance -X- _ I-Outcome
metabolic -X- _ I-Outcome
effects -X- _ I-Outcome
while -X- _ I-Outcome
minimizing -X- _ I-Outcome
the -X- _ I-Outcome
side -X- _ I-Outcome
effects. -X- _ I-Outcome
This -X- _ O
was -X- _ O
observed -X- _ O
in -X- _ O
the -X- _ O
studies -X- _ O
on -X- _ O
molecular -X- _ O
dynamics -X- _ O
simulations -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
on -X- _ O
absorption -X- _ O
, -X- _ O
distribution -X- _ O
, -X- _ O
metabolism -X- _ O
, -X- _ O
and -X- _ O
excretion -X- _ O
, -X- _ O
that -X- _ O
these -X- _ B-Outcome
novel -X- _ I-Outcome
dual -X- _ I-Outcome
agonists -X- _ I-Outcome
not -X- _ I-Outcome
only -X- _ I-Outcome
possessed -X- _ I-Outcome
the -X- _ I-Outcome
same -X- _ I-Outcome
function -X- _ I-Outcome
as -X- _ I-Outcome
ragaglitazar -X- _ I-Outcome
( -X- _ I-Outcome
an -X- _ I-Outcome
investigational -X- _ I-Outcome
drug -X- _ I-Outcome
developed -X- _ I-Outcome
by -X- _ I-Outcome
Novo -X- _ I-Outcome
Nordisk -X- _ I-Outcome
for -X- _ I-Outcome
treating -X- _ I-Outcome
type -X- _ I-Outcome
2 -X- _ I-Outcome
diabetes -X- _ I-Outcome
) -X- _ I-Outcome
did -X- _ I-Outcome
in -X- _ I-Outcome
activating -X- _ I-Outcome
PPARα -X- _ I-Outcome
and -X- _ I-Outcome
PPARγ -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
they -X- _ I-Outcome
also -X- _ I-Outcome
had -X- _ I-Outcome
more -X- _ I-Outcome
favorable -X- _ I-Outcome
conformation -X- _ I-Outcome
for -X- _ I-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
two -X- _ I-Outcome
receptors. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
residues -X- _ I-Outcome
involved -X- _ I-Outcome
in -X- _ I-Outcome
forming -X- _ I-Outcome
the -X- _ I-Outcome
binding -X- _ I-Outcome
pockets -X- _ I-Outcome
of -X- _ I-Outcome
PPARα -X- _ I-Outcome
and -X- _ I-Outcome
PPARγ -X- _ I-Outcome
among -X- _ I-Outcome
the -X- _ I-Outcome
top -X- _ I-Outcome
ten -X- _ I-Outcome
compounds -X- _ I-Outcome
are -X- _ I-Outcome
explicitly -X- _ I-Outcome
presented -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
this -X- _ I-Outcome
will -X- _ I-Outcome
be -X- _ I-Outcome
very -X- _ I-Outcome
useful -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
in-depth -X- _ I-Outcome
conduction -X- _ I-Outcome
of -X- _ I-Outcome
mutagenesis -X- _ I-Outcome
experiments. -X- _ I-Outcome
It -X- _ O
is -X- _ O
anticipated -X- _ O
that -X- _ O
the -X- _ O
ten -X- _ O
compounds -X- _ O
may -X- _ O
become -X- _ O
potential -X- _ O
drug -X- _ O
candidates -X- _ O
, -X- _ O
or -X- _ O
at -X- _ O
the -X- _ O
very -X- _ O
least -X- _ O
, -X- _ O
the -X- _ O
findings -X- _ O
reported -X- _ O
here -X- _ O
may -X- _ O
stimulate -X- _ O
new -X- _ O
strategies -X- _ O
or -X- _ O
provide -X- _ O
useful -X- _ O
insights -X- _ O
for -X- _ O
designing -X- _ O
new -X- _ O
and -X- _ O
more -X- _ O
powerful -X- _ O
dual-agonist -X- _ O
drugs -X- _ O
for -X- _ O
treating -X- _ B-Patient
type -X- _ I-Patient
2 -X- _ I-Patient
diabetes -X- _ I-Patient
. -X- _ O

